Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics

Protein and Peptide Letters

Volumn 16, Issue 5, 2009, Pages 539-542

  Wong, Kwong Fai ^a   Luk, John M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti microbial peptide; BPIP; CD18; Endotoxin neutralizing peptide; Gram negative sepsis

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CD18 ANTIGEN; ENDOTOXIN; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SEPSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD18; ANTIMICROBIAL CATIONIC PEPTIDES; ENDOTOXINS; GRAM-NEGATIVE BACTERIA; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; SEPSIS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 67649385970     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788167761     Document Type: Article

References (30)

1. Hack, C.E.; Aarden, L.A.; Thijs, L.G. Role of cytokines in sepsis.Adv. Immunol., 1997, 66, 101-195.
2. Russell, J.A. Management of sepsis. N. Engl. J. Med., 2006,355(16), 1699-1713.
3. Rice, T.W.; Bernard, G.R. Therapeutic intervention and targets for sepsis. Annu. Rev. Med., 2005, 56, 225-248.
4. Bone, R.C.; Balk, R.A.; Fein, A.M.; Perl, T.M.; Wenzel, R.P.; Reines, H.D.; Quenzer, R.W.; Iberti, T.J.; Macintyre, N.; Schein, R.M. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit. Care Med., 1995, 23(6), 994-1006.
5. Leaver, S.K.; Finney, S.J.; Burke-Gaffney, A.; Evans, T.W. Sepsis since the discovery of Toll-like receptors: Disease concepts and therapeutic opportunities. Crit. Care Med., 2007, 35(5), 1404-1410.
6. Reinhart, K.; Gluck, T.; Ligtenberg, J.; Tschaikowsky, K.; Bruin- ing, A.; Bakker, J.; Opal, S.; Moldawer, L.L.; Axtelle, T.; Turner, T.; Souza, S.; Pribble, J. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med., 2004, 32(5), 11001108.
7. Ziegler, E.J.; Fisher, C.J., Jr.; Sprung, C.L.; Straube, R.C.; Sadoff, J.C.; Foulke, G.E.; Wortel, C.H.; Fink, M.P.; Dellinger, R.P.; Teng,N.N.; et. al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med., 1991, 324(7), 429-436.
8. Weiss, J.; Elsbach, P.; Olsson, I.; Odeberg, H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem., 1978, 253(8), 2664-2672.
9. Gazzano-Santoro, H.; Parent, J.B.; Grinna, L.; Horwitz, A.; Parsons, T.; Theofan, G.; Elsbach, P.; Weiss, J.; Conlon, P.J. High- affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun., 1992, 60(11), 4754-4761.
10. Rietschel, E.T.; Kirikae, T.; Schade, F.U.; Mamat, U.; Schmidt, G.; Loppnow, H.; Ulmer, A.J.; Zahringer, U.; Seydel, U.; Di Padova, F.; et. al. Bacterial endotoxin: molecular relationships of structure to activity and function. Faseb. J., 1994, 8(2), 217-225.
11. Horwitz, A.H.; Ammons, W.S.; Bauer, R.J.; Dedrick, R.; Nadell, R.; Williams, R.E.; Liu, P.S. rBPI(10-193) is secreted by CHO cells and retains the activity of rBPI21. J. Endotoxin Res., 2004, 70(2), 97-106.
12. Ooi, C.E.; Weiss, J.; Doerfler, M.E.; Elsbach, P. Endotoxin neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J. Exp. Med., 1991, 174(3), 649-655.
13. Ooi, C.E.; Weiss, J.; Elsbach, P.; Frangione, B.; Mannion, B. A 25- kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J. Biol. Chem., 1987, 262(31), 14891-14894.
14. Lin, Y.; Ammons, W.S.; Leach, W.J.; Kung, A.H. Protective effects of a recombinant N-terminal fragment of bactericidal/ permeability increasing protein on endotoxic shock in conscious rabbits. Shock, 1994, 2(5), 324-331.
15. Lechner, A.J.; Lamprech, K.E.; Johanns, C.A.; Matuschak, G.M. The recombinant 23-kDa N-terminal fragment of bactericidal/permeability-increasing protein (rBPI23) decreases Es- cherichia coli-induced mortality and organ injury during immuno- suppression-related neutropenia. Shock, 1995, 4(4), 298-306.
16. Evans, T.J.; Carpenter, A.; Moyes, D.; Martin, R.; Cohen, J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/ permeability-increasing protein in an animal model of gram-negative sepsis. J. Infect. Dis., 1995, 171(1), 153-160.
17. Demetriades, D.; Smith, J.S.; Jacobson, L.E.; Moncure, M.; Minei, J.; Nelson, B.J.; Scannon, P.J. Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. J. Trauma., 1999, 46(4), 667-676; discussion 676-667.
18. Levin, M.; Quint, P.A.; Goldstein, B.; Barton, P.; Bradley, J.S.;Shemie, S.D.; Yeh, T.; Kim, S.S.; Cafaro, D.P.; Scannon, P.J.; Gi roir, B.P. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningo- coccal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet, 2000, 356(9234), 961-967.
19. Giroir, B.P.; Quint, P.A.; Barton, P.; Kirsch, E.A.; Kitchen, L.;Goldstein, B.; Nelson, B.J.; Wedel, N.J.; Carroll, S.F.; Scannon,.J. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet, 1997, 350(9089), 1439-1443.
20. De Smet, K.; Contreras, R. Human antimicrobial peptides: defens- ins, cathelicidins and histatins. Biotechnol. Lett., 2005, 27(18),1337-1347.
21. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415(6870), 389-395.
22. Boman, H.G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol., 1995, 13,. 61-92.
23. Larrick, J.W.; Hirata, M.; Balint, R.F.; Lee, J.; Zhong, J.; Wright,S.C. Human CAP18: a novel antimicrobial lipopolysaccharide- binding protein. Infect. Immun., 1995, 63(4), 1291-1297.
24. Rosenfeld, Y.; Papo, N.; Shai, Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem., 2006, 281(3), 1636-1643.
25. Wright, S.D.; Levin, S.M.; Jong, M.T.; Chad, Z.; Kabbash, L.GCR3 (CD11b/CD18) expresses one binding site for Arg-Gly-Asp containing peptides and a second site for bacterial lipopolysaccha ride. J. Exp. Med., 1989, 169(1), 175-183.
26. Wright, S.D.; Jong, M.T. Adhesion-promoting receptors on humanmacrophages recognize Escherichia coli by binding to lipopolysac- haride. J. Exp. Med., 1986, 164(6), 1876-1888.
27. Ingalls, R.R.; Golenbock, D.T. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J. Exp. Med., 1995,181(4), 1473-1479.
28. Flaherty, S.F.; Golenbock, D.T.; Milham, F.H.; Ingalls, R.R.CD11/CD18 leukocyte integrins: new signaling receptors for bacterial endotoxin. J. Surg. Res., 1997, 73(1), 85-89.
29. Wong, K.F.; Luk, J.M.; Cheng, R.H.; Klickstein, L.B.; Fan, S.T.Characterization of two novel LPS-binding sites in leukocyte in- tegrin {beta}A domain. FASEB J., 2007, 21(12), 3231-3239.
30. Nagaoka, I.; Hirota, S.; Niyonsaba, F.; Hirata, M.; Adachi, Y.; Tamura, H.; Heumann, D. Cathelicidin family of antibacterial pep- tides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J. Immunol., 2001, 167(6), 3329-3338.